Thalia Therapeutics
Summary active Updated Jun 28, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Thalia Therapeutics plc is a London-based clinical-stage biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease 12. On 24 June 2026, the company announced the acquisition of Sanmirna Therapeutics, Inc. — a US corporation holding an exclusive licence to miRisten, an anti-microRNA-126 therapy for Acute Myeloid Leukaemia — for initial consideration of £3.675 million with deferred milestone payments of up to £13 million 12. The acquisition transitions Thalia into a clinical-stage RNA therapeutics business 3.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-24 | Placing & Subscription | £2.75M | Premier Miton | Directors, NLC Ventures Netherlands, NLC Health Impact Fund, City of Hope 123 |
The fundraise was conducted via the placing and subscription of 458,333,333 new ordinary shares at 0.6p per share, conditional on AGM approval set for 17 July 2026 1. Directors subscribed for £1,117,500 (40% of the fundraise) 1.
What Investors Say
No independently sourced investor quotes incorporated at this time.
What Founders Say
“This is an exciting and transformative opportunity to accelerate our clinical-stage oncology pipeline and diversify our RNA therapeutics pipeline.”
— Dr. David Solomon, CEO, Thalia Therapeutics 12
“The Sanmirna acquisition is value accretive for Thalia shareholders, as it transforms Thalia into a clinical-stage company.”
— Dr. David Solomon, CEO, Thalia Therapeutics 3
Sources
-
BioSpace, “Thalia Therapeutics PLC Announces Acquisition and £2.75 Million Fundraise,” June 24, 2026. Accessed June 2026. https://www.biospace.com/press-releases/thalia-therapeutics-plc-announces-acquisition-and-2-75-million-fundraise↩↩↩↩↩↩
-
European Biotechnology Magazine, “Thalia buys Sanmirna, becomes a clinical-stage RNA company,” June 2026. Accessed June 2026. https://european-biotechnology.com/latest-news/thalia-buys-sanmirna-becomes-a-clinical-stage-rna-company/↩↩↩↩
-
UKTN, “Thalia Therapeutics acquires US firm backed by fundraise,” June 26, 2026. Accessed June 2026. https://www.uktech.news/medtech/thalia-therapeutics-sanmirna-2026062↩↩↩